| scholarly article | Q13442814 |
| P50 | author | Carine J M Doggen | Q114261316 |
| P2093 | author name string | Frits R Rosendaal | |
| Susanne Osanto | |||
| Jeanet W Blom | |||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 715-722 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Malignancies, prothrombotic mutations, and the risk of venous thrombosis. | |
| P478 | volume | 293 |
| Q34436061 | 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism |
| Q46788143 | A Fatal Brain Stroke in Patient with Advanced Breast Cancer Treated with Bevacizumab: A Case Report |
| Q99628784 | A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19 |
| Q42050589 | A Phase I Trial to Evaluate Antibody-Dependent Cellular Cytotoxicity of Cetuximab and Lenalidomide in Advanced Colorectal and Head and Neck Cancer. |
| Q35232931 | A case of severe cerebral embolism after chemotherapy for HER2-positive gastric cancer |
| Q92107792 | A combined marker based on plasma D-dimer and serum albumin levels in patients with nasopharyngeal carcinoma is associated with poor survival outcomes in a retrospective cohort study |
| Q37729777 | A feasibility study to inform the design of a randomized controlled trial to identify the most clinically and cost effective anticoagulation length with low molecular weight heparin in the treatment of cancer associated thrombosis (ALICAT): study pr |
| Q33772964 | A follow-up study of a genome-wide association scan identifies a susceptibility locus for venous thrombosis on chromosome 6p24.1. |
| Q37293267 | A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment |
| Q36318736 | A prospective multicenter study of venous thromboembolism in patients with newly-diagnosed high-grade glioma: hazard rate and risk factors |
| Q42852290 | A rare cause of chest pain in a cancer patient |
| Q95479053 | ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients |
| Q57168017 | Ability of the Khorana score to predict recurrent thromboembolism in cancer patients with ischemic stroke |
| Q51846266 | Acquired Thrombophilia. |
| Q41921010 | Acute cerebral arterial embolism following pemetrexed and carboplatin treatment in non-small-cell lung cancer: A case report |
| Q38213486 | Acute limb ischemia in cancer patients: aggressive treatment is justified |
| Q37774237 | Acute pulmonary embolism. Part 1: epidemiology and diagnosis |
| Q92890872 | Acute saddle pulmonary embolism on 18F-FDG PET/CT: diagnosis by functional imaging |
| Q33384450 | Adjuvant enoxaparin therapy may decrease the incidence of postoperative thrombotic events though does not increase the incidence of postoperative intracranial hemorrhage in patients with meningiomas |
| Q42936068 | An unusual presentation of metastatic adenocarcinoma of lung: a case report |
| Q27002538 | Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage? |
| Q40328448 | Antibiotic use as a marker of acute infection and risk of first and recurrent venous thrombosis. |
| Q64067376 | Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis |
| Q37831345 | Anticoagulant use in cancer patients |
| Q26825228 | Anticoagulants in cancer |
| Q38805398 | Anticoagulants versus cancer. |
| Q24235260 | Anticoagulation for patients with cancer and central venous catheters |
| Q24236648 | Anticoagulation for patients with cancer and central venous catheters |
| Q24193103 | Anticoagulation for people with cancer and central venous catheters |
| Q57689199 | Anticoagulation for people with cancer and central venous catheters |
| Q91659077 | Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials |
| Q24244042 | Anticoagulation for thrombosis prophylaxis in cancer patients with central venous catheters |
| Q24245918 | Anticoagulation for thrombosis prophylaxis in cancer patients with central venous lines |
| Q26740812 | Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis |
| Q37844474 | Anticoagulation in the management of venous thromboembolism in the cancer patient |
| Q33416407 | Antithrombotic therapy in patients with thrombocytopenic cancer: outcomes associated with reduced-dose, low-molecular-weight heparin during hospitalization |
| Q36304793 | Approach to chemotherapy-associated thrombosis |
| Q37894854 | Approach to the treatment, characterization and diagnosis of an acquired auto-antibody directed against factors prothrombin, factor X and factor IX: a case report and review of the literature |
| Q53160538 | Approach to venous thromboembolism in the cancer patient. |
| Q37006635 | Approaches to risk-stratifying cancer patients for venous thromboembolism. |
| Q61454615 | Arterial events in cancer patients-the case of acute coronary thrombosis |
| Q37393394 | Assessing risk of venous thromboembolism in the patient with cancer. |
| Q98183406 | Assessing the risk of venous thromboembolism in multiple myeloma |
| Q35861679 | Assessment of postoperative venous thromboembolism risk in plastic surgery patients using the 2005 and 2010 Caprini Risk score |
| Q35044297 | Association between incident cancer and subsequent stroke |
| Q35987865 | Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism |
| Q92626777 | Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk |
| Q46862524 | Below-knee cast immobilization and the risk of venous thrombosis: results from a large population-based case-control study. |
| Q39016660 | Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies |
| Q26865716 | Biomolecular markers of cancer-associated thromboembolism |
| Q55332820 | Bladder squamous cell cancer accompanied by Trousseau's syndrome: a case report. |
| Q33377454 | Bleeding and thrombosis in acute leukemia: what does the future of therapy look like? |
| Q37416199 | Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer |
| Q47409413 | Body height, mobility, and risk of first and recurrent venous thrombosis. |
| Q36410469 | Breast cancer risk assessment and prevention: a framework for shared decision-making consultations |
| Q34771524 | CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients |
| Q56515861 | COSIMO - patients with active cancer changing to rivaroxaban for the treatment and prevention of recurrent venous thromboembolism: a non-interventional study |
| Q33439089 | Cancer and Venous Thromboembolic Disease: A Review |
| Q36391554 | Cancer and coagulation |
| Q47583555 | Cancer and risk of cerebral venous thrombosis: a case-control study. |
| Q57300629 | Cancer and subsequent risk of venous thromboembolism |
| Q37533816 | Cancer and thrombosis: implications of published guidelines for clinical practice. |
| Q104072365 | Cancer and thrombosis: new insights to an old problem |
| Q33763866 | Cancer and venous thromboembolic disease: from molecular mechanisms to clinical management |
| Q83004214 | Cancer and venous thromboembolism |
| Q34422539 | Cancer and venous thromboembolism. |
| Q38805391 | Cancer associated thrombosis: risk factors and outcomes |
| Q33377449 | Cancer, thrombosis and heparin-induced thrombocytopenia |
| Q59797777 | Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma |
| Q57475170 | Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment |
| Q51496815 | Cancer-Associated Thrombosis: Regulatory Mechanisms and Emerging Directions. |
| Q38748038 | Cancer-Associated Venous Thromboembolism |
| Q37702182 | Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study |
| Q33389006 | Cancer-associated thrombosis. |
| Q57824763 | Cancer-associated thrombosis: The search for the holy grail continues |
| Q37066546 | Cancer-associated thrombosis: clinical presentation and survival |
| Q37419795 | Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. |
| Q38616609 | Cardiac and pericardial tumors: A potential application of positron emission tomography-magnetic resonance imaging |
| Q49909927 | Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome |
| Q45073137 | Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 2. |
| Q89942065 | Case of internal jugular vein thrombosis and fever: Lemierre's syndrome or Trousseau's syndrome? |
| Q28080150 | Causes of venous thrombosis |
| Q99565313 | Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management |
| Q41672009 | Central venous catheter-related thrombosis in senile male patients: New risk factors and predictors |
| Q38857017 | Characteristics and Impacts of Venous Thromboembolism in Patients with Hepatocellular Carcinoma |
| Q36276667 | Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism |
| Q35563035 | Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study |
| Q49487086 | Circulating microRNA expression and their target genes in deep vein thrombosis: A systematic review and bioinformatics analysis |
| Q53292843 | Circulating procoagulant microparticles in cancer patients. |
| Q36187087 | Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer |
| Q95729132 | Clinical Characteristics and Outcomes of Patients with Lung Cancer and Venous Thromboembolism |
| Q35808697 | Clinical Significance of Preoperative Thrombin Time in Patients with Esophageal Squamous Cell Carcinoma following Surgical Resection |
| Q36411972 | Clinical analysis of tumor and non-tumor patients complicated with pulmonary embolism |
| Q33691627 | Clinical characteristics of pulmonary embolism with underlying malignancy |
| Q33759267 | Clinical features from the history and physical examination that predict the presence or absence of pulmonary embolism in symptomatic emergency department patients: results of a prospective, multicenter study |
| Q90375119 | Clinical features of pulmonary embolism in patients with lung cancer: A meta-analysis |
| Q38205701 | Clinical models and biochemical predictors of VTE in lung cancer |
| Q92003942 | Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma |
| Q35368813 | Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes |
| Q58569905 | Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin |
| Q58804954 | Coagulation factor VII gene polymorphisms are not associated with the occurrence or the survival of hepatocellular carcinoma: a report of 37 cases |
| Q37580200 | Colon cancer metastasis in mouse liver is not affected by hypercoagulability due to Factor V Leiden mutation |
| Q36472966 | Colorectal cancer, comorbidity, and risk of venous thromboembolism: assessment of biological interactions in a Danish nationwide cohort |
| Q36595087 | Common genetic risk factors for venous thrombosis in the Chinese population |
| Q48506942 | Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. |
| Q36063263 | Comparison of Venous Thromboembolism after Total Artificial Joint Replacement between Musculoskeletal Tumors and Osteoarthritis of the Knee by a Single Surgeon |
| Q92625601 | Complementary Role of Intervention Radiology in Palliative Care in Oncology Setting |
| Q37763366 | Congenital thrombophilia and central venous catheter-related thrombosis in patients with cancer |
| Q40409105 | Continuation of low-molecular-weight heparin treatment for cancer-related venous thromboembolism: a prospective cohort study in daily clinical practice. |
| Q38232072 | Contributing role of extracellular vesicles on vascular endothelium haemostatic balance in cancer |
| Q49989182 | Controversies in venous thromboembolism: to treat or not to treat superficial vein thrombosis |
| Q90060511 | Correlates, Trends, and Short-Term Outcomes of Venous Thromboembolism in Hospitalized Patients with Hepatocellular Carcinoma |
| Q93062432 | Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States |
| Q49578979 | Cumulative incidence, risk factors and prognostic impact of venous thromboembolism in Japanese patients with advanced gastric cancer |
| Q38233076 | Current advances in understanding and managing secondary brain metastasis |
| Q64936707 | Current and future burden of venous thrombosis: Not simply predictable. |
| Q34610427 | Current concepts of metastasis in melanoma. |
| Q36265574 | Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient |
| Q44578606 | D-dimer as a potential prognostic marker |
| Q37806823 | Deep Vein Thrombosis Prophylaxis in Hospitalized Medical Patients: Current Recommendations, General Rates of Implementation, and Initiatives for Improvement |
| Q49342291 | Deep venous thrombosis in elderly patients as a surgical emergency at King Abdulaziz University Hospital, Jeddah, Saudi Arabia |
| Q36657982 | Development and validation of a predictive model for chemotherapy-associated thrombosis |
| Q39629675 | Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. |
| Q35340016 | Development of a risk-screening tool for cancer survivors to participate in unsupervised moderate- to vigorous-intensity exercise: results from a survey study. |
| Q34208140 | Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment |
| Q38994953 | Diagnosis and management of factor V Leiden. |
| Q37425818 | Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach. |
| Q39907289 | Differential effects of anticoagulants on tumor development of mouse cancer cell lines B16, K1735 and CT26 in lung |
| Q92648688 | Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients |
| Q37216645 | Distinct predictors of pre- versus post-discharge venous thromboembolism after hepatectomy: analysis of 7621 NSQIP patients |
| Q40173427 | Diverse roles of cell-specific hypoxia-inducible factor 1 in cancer-associated hypercoagulation. |
| Q44200568 | Do thrombophilic gene mutations have a role on thromboembolic events in cancer patients? |
| Q88723643 | Effect of post-filter anticoagulation on mortality in patients with cancer-associated pulmonary embolism |
| Q49888849 | Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA). |
| Q57810132 | Effectiveness and safety of oral direct factor Xa inhibitors for the treatment of venous thromboembolism in patients with cancer and/or older age |
| Q47174386 | Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study |
| Q101216950 | Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials |
| Q53101380 | Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. |
| Q90671035 | Efficacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis |
| Q41492090 | Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study. |
| Q40350703 | Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients |
| Q26746904 | Elevated risk of venous thromboembolic events in patients with inflammatory myopathies |
| Q37740291 | Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score |
| Q91755627 | Endogenous sex hormones and risk of venous thromboembolism in young women |
| Q33967101 | Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study |
| Q37935403 | Enoxaparin once daily vs. twice daily dosing for the treatment of venous thromboembolism in cancer patients: a literature summary |
| Q28199907 | Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide |
| Q35860789 | Epidemiology and pathophysiology of cancer-associated thrombosis |
| Q104072361 | Epidemiology and risk factors for cancer-associated thrombosis |
| Q36063535 | Epidemiology and risk factors for venous thrombosis |
| Q37242472 | Epidemiology of cancer-related venous thromboembolism |
| Q41667853 | Epidemiology of venous thromboembolism |
| Q89002090 | Epidemiology, Pathophysiology, and Natural History of Pulmonary Embolism |
| Q49048515 | Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting |
| Q47211898 | Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study |
| Q50197484 | Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma |
| Q33759372 | Evidence for tissue factor phosphorylation and its correlation with protease-activated receptor expression and the prognosis of primary breast cancer. |
| Q33992605 | Experience with multiple control groups in a large population-based case-control study on genetic and environmental risk factors |
| Q92490153 | Extended treatment with non-vitamin K antagonist oral anticoagulants versus low-molecular-weight heparins in cancer patients following venous thromboembolism. A pilot study |
| Q89525477 | External Validation of a Venous Thromboembolic Risk Score for Cancer Outpatients with Solid Tumors: The COMPASS-CAT Venous Thromboembolism Risk Assessment Model |
| Q38543321 | Extracellular DNA and histones: double-edged swords in immunothrombosis |
| Q37175602 | F9 Malmö, factor IX and deep vein thrombosis |
| Q37641282 | Factor V Leiden and activated protein C resistance |
| Q58955398 | Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients-results from the Vienna Cancer And Thrombosis Study (CATS) |
| Q35218582 | Factor V Leiden mutation triggering four major complications to standard dose cisplatin-chemotherapy for testicular seminoma: a case report |
| Q34152374 | Factor V Leiden thrombophilia |
| Q36045799 | Factor V-Leiden Mutation: A Common Risk Factor for Venous Thrombosis among Lebanese Patients |
| Q45852873 | Familial risks of unusual forms of venous thrombosis: a nationwide epidemiological study in Sweden |
| Q33443338 | Fatal pulmonary embolism following splenectomy in a patient with Evan's syndrome: case report and review of the literature. |
| Q90466730 | Fibrinogen gamma gene rs2066865 and risk of cancer-related venous thromboembolism |
| Q36579154 | Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique |
| Q38835475 | Freezing oocytes or embryos after controlled ovarian hyperstimulation in cancer patients: the state of the art. |
| Q39925734 | Frequency of malignancy is high in patients admitted for a first venous thromboembolism episode: an observational study |
| Q98183400 | Genes and proteins associated with the risk for cancer-associated thrombosis |
| Q98183420 | Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations |
| Q34616494 | Genetic variants in Cell Adhesion Molecule 1 (CADM1): a validation study of a novel endothelial cell venous thrombosis risk factor |
| Q35037432 | Genetic variation associated with plasma von Willebrand factor levels and the risk of incident venous thrombosis |
| Q38214971 | Glycosaminoglycans in cancer treatment. |
| Q28078989 | Guidance for the treatment of deep vein thrombosis and pulmonary embolism |
| Q38436339 | Guidelines for the management of cancer and thrombosis - Special aspects in women |
| Q35927808 | Haemostatic alterations in a group of canine cancer patients are associated with cancer type and disease progression |
| Q36617694 | Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States |
| Q83757620 | Hemostatic abnormalities in dogs with carcinoma: a thromboelastographic characterization of hypercoagulability |
| Q38214957 | Heparins and cancer survival: where do we stand? |
| Q34497513 | Hepatic veins as a site of clot formation following liver resection. |
| Q57779012 | High levels of procoagulant factors mediate the association between free thyroxine and the risk of venous thrombosis: the MEGA study |
| Q34160974 | High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients |
| Q42203621 | Higher rate of breast surgery complications in patients with metastatic breast cancer: an analysis of the NSQIP database. |
| Q51035409 | Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, São Paulo, Brazil. |
| Q34250240 | Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006 |
| Q47192469 | Human pancreatic tumors grown in mice release tissue factor-positive microvesicles that increase venous clot size |
| Q37011663 | IVC filters may prevent fatal pulmonary embolism in musculoskeletal tumor surgery |
| Q40227354 | Identification of coagulation gene 3'UTR variants that are potentially regulated by microRNAs |
| Q41618470 | Identification of target gene of venous thromboembolism in patients with lymphoma via microarray analysis |
| Q79673958 | Idiopathic and recurrent thromboembolic phenomena in cancer patients |
| Q33594318 | Idiopathic superficial thrombophlebitis and the incidence of cancer in primary care patients |
| Q45734083 | Idiopathic venous thromboembolism: a potential surrogate for occult cancer |
| Q37972076 | Imaging thrombus in cancer patients with FDG PET-CT. |
| Q92703777 | Impact of Obesity on Surgical Outcomes Following Laminectomy for Spinal Metastases |
| Q99201835 | Impact of Perioperative Multidisciplinary Rehabilitation Pathway on Early Outcomes after Robot-Assisted Radical Cystectomy: A Matched Analysis |
| Q34893956 | Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability |
| Q42704249 | Impact of chemotherapy on venous thromboembolism: comment to: regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study |
| Q57788269 | Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment |
| Q33744868 | Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study |
| Q36251473 | Impact of venous thromboembolism on mortality of elderly Medicare patients with stage III colon cancer |
| Q40644232 | Impact of venous thromboembolism on the natural history of pancreatic adenocarcinoma. |
| Q64228869 | Implementation of an electronic medical record tool for early detection of deep vein thrombosis in the ambulatory oncology setting |
| Q30885659 | Improving accuracy of International Classification of Diseases codes for venous thromboembolism in administrative data |
| Q54948004 | In the nick of time: arterial thrombosis on starting combination chemotherapy in metastatic gastric adenocarcinoma. |
| Q37069353 | Incidence and Risk Factors of Thromboembolism with Multiple Myeloma in the Presence of Death as a Competing Risk: An Empirical Comparison of Statistical Methodologies |
| Q83020519 | Incidence and timing of venous thromboembolism after surgery for gynecological cancer |
| Q89898249 | Incidence of and risk factors for preoperative deep venous thrombosis in patients undergoing gastric cancer surgery |
| Q93048104 | Incidence of and risk factors for totally implantable vascular access device complications in patients with gastric cancer: A retrospective analysis |
| Q92794623 | Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: a single-institutional retrospective cohort analysis (Sapporo CAT study) |
| Q35091342 | Incidence of pulmonary embolism in oncologic outpatients at a tertiary cancer center |
| Q47772034 | Incidence of venous thromboembolism among chemotherapy-treated patients with lung cancer and its association with mortality: a retrospective database study |
| Q33560114 | Incidence of venous thromboembolism and the role of D-dimer as predictive marker in patients with advanced gastric cancer receiving chemotherapy: A prospective study |
| Q38212499 | Incidence of venous thromboembolism following major surgery in Korea: from the Health Insurance Review and Assessment Service database. |
| Q47156509 | Incidence of venous thromboembolism following the neoadjuvant chemotherapy regimen for epithelial type of ovarian cancer |
| Q37037432 | Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma |
| Q48661559 | Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study |
| Q36812718 | Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. |
| Q42703932 | Incidental pulmonary embolism in cancer patients: clinical characteristics and outcome--a comprehensive cancer center experience |
| Q34323247 | Increased activity of cell membrane-associated prothrombinase, fibrinogen-like protein 2, in peripheral blood mononuclear cells of B-cell lymphoma patients |
| Q35481286 | Increased expressions of integrin subunit β1, β2 and β3 in patients with cancer ------correlation analysis between risk factors of VTE and expression of core proteins |
| Q90046363 | Increased risk for cancer after stroke at a young age: etiological relevance or incidental finding? |
| Q54049063 | Increased thrombin generation in a mouse model of cancer cachexia is partially interleukin-6 dependent. |
| Q40655969 | Inferior Vena Cava Filters: Indications, Outcomes, and Evidence |
| Q35948264 | Inferior vena cava filters for primary prophylaxis: when are they indicated? |
| Q46039945 | Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes. |
| Q30664606 | Inferior vena cava filtration in the management of venous thromboembolism: filtering the data |
| Q36149549 | Inflammation, TNFα and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia |
| Q91938828 | Influence of Tumor Thrombus on Occurrence of Distant Venous Thromboembolism and Survival in Patients With Renal Cell Carcinoma After Surgery |
| Q26778920 | Interaction between circulating cancer cells and platelets: clinical implication |
| Q87379170 | Interleukin levels and their potential association with venous thromboembolism and survival in cancer patients |
| Q47245926 | Intermittent pneumatic compression in combination with low-molecular weight heparin in the prevention of venous thromboembolic events in esophageal cancer surgery |
| Q42085774 | Internal Jugular and Subclavian Vein Thrombosis in a Case of Ovarian Cancer |
| Q38757170 | Interventional radiology and the care of the oncology patient |
| Q58028690 | Is coagulation factor VIII a useful marker for colorectal carcinoma? |
| Q36411948 | Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer |
| Q37302477 | Is thrombophilia a major risk factor for deep vein thrombosis of the lower extremities among Lebanese patients? |
| Q91310420 | Is venous thromboembolism a problem in patients with cancer in palliative care? |
| Q52597188 | Ischemic stroke in cancer patients: A review of an underappreciated pathology. |
| Q37331210 | Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism |
| Q88880415 | Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma |
| Q38805402 | LMWH in cancer patients with renal impairment - better than warfarin? |
| Q36264538 | LUNG CANCER AND PULMONARY THROMBOEMBOLISM. |
| Q33683277 | Leukemia and Risk of Venous Thromboembolism: A Meta-analysis and Systematic Review of 144 Studies Comprising 162,126 Patients |
| Q36793722 | Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. |
| Q38555091 | Limiting early mortality: Do's and don'ts in the management of patients with newly diagnosed multiple myeloma |
| Q51108756 | Local low-dose thrombolysis for safe and effective treatment of venous port-catheter thrombosis. |
| Q93092119 | Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort |
| Q47672102 | Long-term Survival Associated with Crizotinib in a Lung Cancer Patient with a Pulmonary Artery Embolism |
| Q28732904 | Long-term survival in a large cohort of patients with venous thrombosis: incidence and predictors |
| Q37243904 | Long-term use of daily subcutaneous low molecular weight heparin in cancer patients with venous thromboembolism: why hesitate any longer? |
| Q40217071 | Longitudinal analysis of hemostasis biomarkers in cancer patients during antitumor treatment. |
| Q34905736 | Low C-reactive protein levels in a traditional West-African population living in a malaria endemic area. |
| Q38243883 | Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis |
| Q37943009 | Low molecular weight heparins in the treatment of lung cancer |
| Q38017363 | Low-molecular-weight heparin and survival in lung cancer |
| Q33399333 | Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer |
| Q37345018 | Lower extremity deep vein thrombosis after heavy exertion |
| Q44097204 | Lymphoma and venous thromboembolism: influence on mortality |
| Q81617082 | MET orchestrates cancer and blood coagulation |
| Q40513571 | Male-specific risk of first and recurrent venous thrombosis: a phylogenetic analysis of the Y chromosome |
| Q37339051 | Malignancies and catastrophic anti-phospholipid syndrome |
| Q34195599 | Management of inherited thrombophilia: guide for genetics professionals |
| Q39794332 | Management of venous thromboembolism in cancer patients: the economic burden of hospitalizations |
| Q36812767 | Management of venous thromboembolism in patients with cancer: role of dalteparin |
| Q36590609 | Management of venous thromboembolism in the elderly |
| Q90480677 | Managing thrombosis in cancer patients |
| Q34521728 | Massive hypercoagulable state despite full-dose anticoagulant treatment in a patient with occult malignancy: considerations concerning chemotherapy without definitive diagnosis |
| Q53043932 | Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma. |
| Q55432473 | Mecanismos do tromboembolismo venoso no câncer: uma revisão da literatura. |
| Q97520716 | Mechanisms and biomarkers of cancer-associated thrombosis |
| Q35266365 | Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism |
| Q44096551 | Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab |
| Q37837956 | Microparticles, malignancy and thrombosis |
| Q36233784 | Modeling and simulation of procoagulant circulating tumor cells in flow |
| Q33743421 | Modelling pulmonary microthrombosis coupled to metastasis: distinct effects of thrombogenesis on tumorigenesis |
| Q57300330 | Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism |
| Q38230423 | Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications |
| Q89777016 | Multiplexed targeted proteomic assay to assess coagulation factor concentrations and thrombosis-associated cancer |
| Q52339910 | Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. |
| Q35840361 | Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2. |
| Q47797800 | Need for inferior vena cava filters in cancer patients: a surrogate marker for poor outcome |
| Q41729508 | Neoadjuvant chemoradiation for rectal cancer is not associated with higher rates of thromboembolism |
| Q49570630 | Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system |
| Q38831847 | New anticoagulants for the treatment of venous thromboembolism |
| Q47742942 | New data for venous thromboembolism in patients with small cell lung cancer: A review |
| Q61997134 | New diagnosis of cancer and the risk of subsequent cerebrovascular events |
| Q37307380 | New insights into cancer-associated thrombosis |
| Q38223377 | New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients |
| Q36179343 | Next-Generation Sequencing and In Vitro Expression Study of ADAMTS13 Single Nucleotide Variants in Deep Vein Thrombosis |
| Q90568724 | Non-Vitamin K Antagonist Oral Anticoagulants in Medical Conditions at High Risk of Thromboembolism beyond Atrial Fibrillation |
| Q38964210 | Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease |
| Q40229105 | Occult cancer-related first venous thromboembolism is associated with an increased risk of recurrent venous thromboembolism |
| Q36073511 | Occurrence of Deep Vein Thrombosis among Hospitalized Non-Surgical Japanese Patients |
| Q30620082 | Older renal cell cancer patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data |
| Q30982789 | Older soft tissue sarcoma patients experience increased rates of venous thromboembolic events: a retrospective cohort study of SEER-Medicare data |
| Q37740307 | Open issues on bleeding and thrombosis in acute promyelocytic leukemia. |
| Q36085844 | Optimal cytoreductive surgery for underlying ovarian cancer associated with deep venous thrombosis without placement of inferior vena cava filter: A case report and literature review |
| Q64993263 | Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. |
| Q47831423 | Outcomes after inferior vena cava filter placement in cancer patients diagnosed with pulmonary embolism: risk for recurrent venous thromboembolism. |
| Q38095148 | Overview and assessment of risk factors for pulmonary embolism |
| Q37973346 | Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia. |
| Q38129719 | Pathologies at the nexus of blood coagulation and inflammation: thrombin in hemostasis, cancer, and beyond |
| Q91979008 | Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients |
| Q38084608 | Pathophysiology and management of thrombosis in cancer: 150 years of progress |
| Q38161521 | Patient selection for thromboprophylaxis in medical inpatients |
| Q52600653 | Patients' Experience of Living with Cancer-associated thrombosis in Spain (PELICANOS). |
| Q35142746 | Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study |
| Q36406741 | Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study |
| Q48105964 | Performance of Current Thromboembolism Risk Assessment Tools in Patients With Gastric Cancer and Validity After First Treatment. |
| Q48683678 | Performance of Khorana Risk Score for Prediction of Venous Thromboembolism in Patients With Hepatocellular Carcinoma. |
| Q39062472 | Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occult cancer in patients with cryptogenic stroke |
| Q47400340 | Platelet count as a predictor of metastasis and venous thromboembolism in patients with cancer |
| Q89883973 | Platelet-Derived Microparticles are an Important Biomarker in Patients with Cancer-Associated Thrombosis |
| Q38805421 | Polymorphisms of the coagulation system and risk of cancer |
| Q50531670 | Post-operative pharmacologic thromboprophylaxis after major hepatectomy: does peripheral venous thromboembolism prevention outweigh bleeding risks? |
| Q38214962 | Predicting recurrent venous thromboembolism in cancer: is it possible? |
| Q90655806 | Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP) |
| Q64118918 | Predictive factors for cancer-associated thrombosis in a large retrospective single-center study |
| Q41486100 | Predictive value of factor VIII levels for recurrent venous thrombosis: results from the MEGA follow-up study. |
| Q46085597 | Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). |
| Q38805443 | Predictors of recurrent venous thromboembolism and bleeding on anticoagulation. |
| Q33810510 | Predictors of venous thromboembolism in patients with advanced common solid cancers |
| Q33781172 | Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study |
| Q46337264 | Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study |
| Q57300262 | Preoperative plasma D-dimer predicts 1-year survival in colorectal cancer patients with absence of venous thromboembolism (VTE): a prospective clinical cohort study |
| Q35052025 | Preparation and characterization of anti-tissue factor single-chain variable fragment antibody for cancer diagnosis. |
| Q54571473 | Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients. |
| Q90190073 | Preventing Venous Thromboembolism in Ambulatory Patients with Cancer: A Narrative Review |
| Q38686333 | Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: Focus on Drug Therapy |
| Q41877145 | Prevention and treatment of venous thromboembolism in patients with cancer |
| Q24633010 | Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q37038414 | Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma |
| Q89448175 | Prevention of venous thromboembolism in patients with cancer with direct oral anticoagulants: A systematic review and meta-analysis |
| Q49965472 | Primary Thromboprophylaxis in Individuals without Cancer Admitted to a Geriatric Palliative Care Unit |
| Q35860785 | Primary prevention of venous thromboembolism in medical and surgical oncology patients |
| Q38079522 | Primary venous thromboembolism prophylaxis in ambulatory cancer patients |
| Q92978766 | Prognosis and risk factors in older patients with lung cancer and pulmonary embolism: a propensity score matching analysis |
| Q37397828 | Prognostic role of D-dimer for in-hospital and 1-year mortality in exacerbations of COPD. |
| Q35532514 | Promotion of experimental thrombus formation by the procoagulant activity of breast cancer cells. |
| Q37310820 | Prophylactic and therapeutic anticoagulation for thrombosis: major issues in oncology |
| Q48015257 | Prophylaxis and treatment of venous thromboembolism in patients with cancer: the Saudi clinical practice guideline |
| Q87051993 | Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer |
| Q37364238 | Proteasome inhibitors enhance endothelial thrombomodulin expression via induction of Krüppel-like transcription factors |
| Q39872943 | Prothrombotic state in senile patients with acute exacerbations of chronic obstructive pulmonary disease combined with respiratory failure |
| Q52722990 | Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism. |
| Q82663075 | Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab |
| Q37133224 | Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease |
| Q38017587 | Quality of life and supportive care for patients with metastatic renal cell carcinoma. |
| Q92983742 | RNA expression and risk of venous thromboembolism in lung cancer |
| Q43163289 | Randomised high- and low-dose heparin prophylaxis in patients undergoing thoracotomy for benign and malignant disease: effect on thrombo-elastography |
| Q47177842 | Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial |
| Q90683374 | Rare cause of repeated pulmonary embolism: a case of primary pleural squamous cell carcinoma and literature review |
| Q64966446 | Real-world features associated with cancer-related venous thromboembolic events. |
| Q41705428 | Recurrence of Venous Thromboembolism in Patients With Cancer Treated With Warfarin |
| Q49252439 | Recurrent mutations in a SERPINC1 hotspot associate with venous thrombosis without apparent antithrombin deficiency |
| Q40229169 | Recurrent venous thrombosis related to overweight and obesity: results from the MEGA follow-up study |
| Q37060686 | Regional lymph node metastases are a strong risk factor for venous thromboembolism: results from the Vienna Cancer and Thrombosis Study |
| Q53665784 | Reply to letter re: anticoagulant therapy in oncologic patients undergoing venous stenting for superior vena cava syndrome and other interventional procedures. |
| Q41003946 | Retrievable inferior vena cava filters in patients with cancer are safe but are they beneficial? |
| Q92001912 | Retrospective Cohort Study of Venous Thromboembolism Rates in Ambulatory Cancer Patients: Association With Khorana Score and Other Risk Factors |
| Q88561089 | Retrosternal Reconstruction Can be a Risk Factor for Upper Extremity Deep Vein Thrombosis After Esophagectomy |
| Q41443206 | Risk Factors for Venous Thromboembolism Among Reproductive Age Women. |
| Q41851756 | Risk Factors of a Pulmonary Thromboembolism After Colorectal Surgery |
| Q55221662 | Risk Factors, Biomarkers, Etiology, Outcome and Prognosis of Ischemic Stroke in Cancer Patients |
| Q64247144 | Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism |
| Q49873887 | Risk and incidence of perioperative deep vein thrombosis in patients undergoing gastric cancer surgery |
| Q38017362 | Risk assessment for cancer-associated thrombosis: what is the best approach? |
| Q37956590 | Risk assessment models for cancer-associated venous thromboembolism |
| Q35432469 | Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer |
| Q33606182 | Risk factors and prognosis of pulmonary embolism in patients with lung cancer |
| Q36625144 | Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study |
| Q46720316 | Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients |
| Q34988616 | Risk factors for venous and arterial thrombosis |
| Q38214965 | Risk factors for venous thromboembolism in cancer: novel findings from the Vienna Cancer and Thrombosis Study (CATS). |
| Q80485832 | Risk factors of venous thromboembolism in thai patients |
| Q40079432 | Risk of Arterial Thromboembolism in Patients With Cancer. |
| Q91979018 | Risk of Thrombosis in Cancer: Clinical Factors and Role of Primary Prophylaxis |
| Q87944907 | Risk of post-operative venous thromboembolism in patients with meningioma |
| Q38676175 | Risk of severe pulmonary embolism in cancer patients receiving bevacizumab: Results from a meta-analysis of published and unpublished data |
| Q35118211 | Risk of site-specific cancer in incident venous thromboembolism: a population-based study |
| Q34428728 | Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation |
| Q55396746 | Risk of venous thromboembolism in association with factor V leiden in cancer patients - The EDITH case-control study. |
| Q37849250 | Risk of venous thromboembolism in bone and soft-tissue sarcoma patients undergoing surgical intervention: a report from prior to the initiation of SCIP measures |
| Q37129682 | Risk of venous thromboembolism in hospitalised cancer patients in England-a cohort study |
| Q27005043 | Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis |
| Q93009468 | Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation |
| Q40977633 | Risk of venous thrombosis after arthroscopy of the knee: results from a large population-based case-control study. |
| Q46348165 | Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. |
| Q47990863 | Risk of venous thrombosis in patients with pancreatic adenocarcinoma |
| Q40740906 | Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors |
| Q44006721 | Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations |
| Q37142210 | Risk stratification and venous thromboprophylaxis in hospitalized medical and cancer patients |
| Q38214964 | Risk stratification strategies for cancer-associated thrombosis: an update |
| Q49964977 | Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial. |
| Q84706716 | SEOM guidelines on thrombosis in cancer patients |
| Q47432203 | Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery. |
| Q38523012 | Safety of anticoagulant treatment in cancer patients |
| Q33429840 | Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series |
| Q49123780 | Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients |
| Q38821459 | Sex-specific differences in the presenting location of a first venous thromboembolism. |
| Q40679079 | Significance of venous thromboembolism in women with cervical cancer. |
| Q35959692 | Single Nucleotide Variant rs2232710 in the Protein Z-Dependent Protease Inhibitor (ZPI, SERPINA10) Gene Is Not Associated with Deep Vein Thrombosis |
| Q98225445 | Small bowel obstruction caused by 18FDG-negative ileocecal metastasis of lobular breast carcinoma |
| Q43998111 | Socioeconomic factors and concomitant diseases are related to the risk for venous thromboembolism during long time follow-up |
| Q35004732 | Standard perioperative management in gastrointestinal surgery |
| Q56968545 | Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study |
| Q88810481 | Statin use and venous thromboembolism in cancer: A large, active comparator, propensity score matched cohort study |
| Q43770339 | Statins, aspirin and risk of venous thromboembolic events in breast cancer patients |
| Q43193000 | Superior sagittal sinus thrombosis as the initial presentation of renal cell carcinoma. |
| Q30790979 | Survival analysis of time-to-event data in respiratory health research studies |
| Q28754730 | Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis |
| Q24198132 | Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters |
| Q24234208 | Systemic treatments for the prevention of venous thrombo-embolic events in pediatric cancer patients with tunnelled central venous catheters |
| Q57605571 | Targeted sequencing to identify novel genetic risk factors for deep vein thrombosis: a study of 734 genes |
| Q34495463 | Targeting angiogenesis with integrative cancer therapies |
| Q50624082 | Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10. |
| Q89243138 | The Application of Current Proposed Venous Thromboembolism Risk Assessment Model for Ambulatory Patients With Cancer |
| Q37129768 | The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis. |
| Q34785094 | The Impact of Cancer on the Clinical Outcome of Patients After Inferior Vena Cava Filter Placement: A Retrospective Cohort Study |
| Q84140444 | The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients |
| Q52719266 | The Platelet Lifeline to Cancer: Challenges and Opportunities. |
| Q37233818 | The Prophylaxis of Venous Thromboembolism |
| Q42924611 | The Risk of Deep Venous Thrombosis Associated With Injectable Depot–Medroxyprogesterone Acetate Contraceptives or a Levonorgestrel Intrauterine Device |
| Q58776758 | The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated Thrombosis |
| Q36888938 | The Role of Inferior Vena Cava Filters in Cancer Patients |
| Q51165894 | The Role of New Oral Anticoagulants (NOACs) in Cancer Patients. |
| Q37261341 | The application of clinical variables and models to predict pulmonary embolism in cancer patients: a comprehensive single cancer center experience |
| Q44273811 | The association of cancer and venous thrombosis: yes, Trousseau is right...again! |
| Q36415367 | The clinical characteristics of pulmonary embolism in patients with malignancy: a single medical institutional experience |
| Q55431258 | The comparison between Caprini and Padua VTE risk assessment models for hospitalised cancer patients undergoing chemotherapy at the tertiary oncology department in Poland: is pharmacological thromboprophylaxis overused? |
| Q92722756 | The direct oral anticoagulants rivaroxaban and dabigatran do not inhibit orthotopic growth and metastasis of human breast cancer in mice |
| Q38005356 | The double edged sword of bleeding and clotting from VEGF inhibition in renal cancer patients |
| Q37187791 | The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents. |
| Q85205795 | The impact of bortezomib on the risk of thrombosis in multiple myeloma |
| Q38741168 | The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. |
| Q35683034 | The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients |
| Q37374557 | The incidence and risk of venous thromboembolism associated with cancer and nonsurgical cancer treatment. |
| Q46261724 | The incidence of venous thromboembolism among patients with primary lung cancer |
| Q57788214 | The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the Tromsø study |
| Q55457563 | The influence of heparin on coagulation function of patients undergoing video-assisted major thoracic surgery. |
| Q26740349 | The lung cancer nurse role in the management of paraneoplastic syndromes in lung cancer |
| Q58739465 | The optimal anticoagulant therapy for mechanical heart valves in a gallbladder cancer patient with hepatic metastases: A case report |
| Q26765326 | The origin and onset of acute venous thrombus |
| Q36511032 | The pathogenesis of venous thromboembolism in cancer: emerging links with tumour biology |
| Q38017369 | The protein C pathway in cancer metastasis |
| Q33347978 | The risk of cancer progression in women with gynecological malignancies and thrombophilic polymorphisms: a pilot case-control study |
| Q44735545 | The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy |
| Q37740299 | The role of activated protein C in cancer progression |
| Q33625063 | The role of thromboprophylaxis in cancer patients: emerging data. |
| Q33639274 | The safety profile of preoperative administration of heparin for thromboprophylaxis in Chinese patients intended for thoracoscopic major thoracic surgery: a pilot randomized controlled study |
| Q35034831 | The thrombotic potential of circulating tumor microemboli: computational modeling of circulating tumor cell-induced coagulation |
| Q33888679 | Thrombembolic complications after total ankle replacement |
| Q60957493 | Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study |
| Q39467158 | Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivo: procoagulant nature of osteosarcoma |
| Q38214955 | Thrombo-hemorrhagic deaths in acute promyelocytic leukemia |
| Q46859602 | Thromboembolic complications following ankle prosthesis implantation |
| Q38083556 | Thromboembolic disease in cancer patients |
| Q93353851 | Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study |
| Q36588644 | Thromboembolism in cancer patients: pathogenesis and treatment |
| Q37076622 | Thromboembolism in gastrointestinal cancers. |
| Q37006639 | Thrombophilia and risk of venous thrombosis in patients with cancer |
| Q37939117 | Thrombophilia, left ventricular dysfunction and intracardiac thrombi in children |
| Q37863640 | Thrombophilic state in cancer, part I: biology, incidence, and risk factors |
| Q50126297 | Thromboprophylaxis and the route of administration of chemotherapy in testicular cancer patients in German-speaking countries. |
| Q51110193 | Thromboprophylaxis during chemotherapy after advanced cancer. |
| Q39873769 | Thromboprophylaxis during chemotherapy in patients with advanced cancer |
| Q33379238 | Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis |
| Q26995284 | Thromboprophylaxis guidelines in cancer with a primary focus on ambulatory patients receiving chemotherapy: a review from the Southern Network on Adverse Reactions (SONAR) |
| Q37023306 | Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer |
| Q92853004 | Thrombosis Risk Associated with Head and Neck Cancer: A Review |
| Q43026378 | Thrombosis after liver transplantation for hepatocellular carcinoma |
| Q28200293 | Thrombosis after travel |
| Q56339353 | Thrombosis and cancer |
| Q52562627 | Thrombosis in Thyroid Cancer. |
| Q33437325 | Thrombosis in the setting of cancer. |
| Q36947164 | Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients |
| Q35832620 | Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice |
| Q36470049 | Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. |
| Q36215088 | Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival |
| Q33255313 | Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). |
| Q38647343 | Treating patients with cancer and acute venous thromboembolism |
| Q90448603 | Treatment of pulmonary thromboembolism with edoxaban in a cancer patient with borderline fulfillment of the dose reduction criteria |
| Q37773994 | Treatment of thromboembolism in cancer patients |
| Q41965622 | Trousseau's syndrome in a patient with advanced stage gastric cancer |
| Q28301882 | Trousseau's syndrome: multiple definitions and multiple mechanisms |
| Q35579053 | Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF. |
| Q57810885 | Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells |
| Q92571444 | Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients |
| Q52805260 | Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. |
| Q36934000 | Use of ED and hospital services for patients with acute leukemia after induction therapy: one year follow-up |
| Q45065598 | Use of direct oral anticoagulants in patients on immunomodulatory agents. |
| Q53161523 | Use of thromboprophylaxis in palliative care patients: a survey among experts in palliative care, oncology, intensive care, and anticoagulation. |
| Q46497825 | Validation of the Ottawa prognostic score for the prediction of recurrent venous thromboembolism in patients with cancer-associated thrombosis |
| Q39446006 | Validation of the clinical prediction rule for recurrent venous thromboembolism in cancer patients: the Ottawa score |
| Q53142866 | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. |
| Q35920045 | Variation in thromboembolic complications among patients undergoing commonly performed cancer operations |
| Q38716326 | Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer |
| Q47965170 | Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors. |
| Q60960811 | Venous Thromboembolism in Asian Patients with Pancreatic Cancer Following Palliative Chemotherapy: Low Incidence but a Negative Prognosticator for Those with Early Onset |
| Q26741697 | Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants |
| Q38381351 | Venous Thromboembolism in Cancer: Frequently Asked Questions When Guidelines are Inconclusive |
| Q38944457 | Venous Thromboembolism in Patients Diagnosed With Lung Cancer |
| Q38983946 | Venous Thromboembolism in Physically Active People: Considerations for Risk Assessment, Mainstream Awareness and Future Research |
| Q28607612 | Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Case-Control Studies |
| Q33408419 | Venous access catheter-related thrombosis in patients with cancer |
| Q27008491 | Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance |
| Q24631121 | Venous thromboembolic disease |
| Q36636027 | Venous thromboembolic disease and cancer |
| Q37416512 | Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors |
| Q48559598 | Venous thromboembolism after hepatic resection: analysis of 5,706 patients |
| Q38411161 | Venous thromboembolism after major orthopaedic surgery: a population-based cohort study. |
| Q45034330 | Venous thromboembolism after major urologic oncology surgery: a focus on the incidence and timing of thromboembolic events after 27,455 operations. |
| Q50639422 | Venous thromboembolism after nephrectomy: incidence, timing and associated risk factors from a national multi-institutional database. |
| Q37584108 | Venous thromboembolism and cancer risk |
| Q33608869 | Venous thromboembolism and cancer risk among elderly adults in the United States |
| Q37688960 | Venous thromboembolism and cancer: a systematic review |
| Q57407574 | Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database |
| Q33419213 | Venous thromboembolism in cancer patients |
| Q26852015 | Venous thromboembolism in cancer patients: an underestimated major health problem |
| Q38751462 | Venous thromboembolism in cancer patients: risk assessment, prevention and management |
| Q59133390 | Venous thromboembolism in chronic lymphocytic leukemia: a Danish nationwide cohort study |
| Q98183385 | Venous thromboembolism in palliative care patients: what do we know? |
| Q34113138 | Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma |
| Q37169120 | Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival |
| Q37867284 | Venous thromboembolism in patients with cancer: an overview for pharmacists using a case-based approach |
| Q54975217 | Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). |
| Q36535503 | Venous thromboembolism in patients with diffuse large B-cell lymphoma |
| Q43855755 | Venous thromboembolism in patients with head and neck cancer after surgery |
| Q50726885 | Venous thromboembolism in patients with myeloma: incidence and risk factors in a "real-world" population. |
| Q36916924 | Venous thromboembolism prevention in cancer patients: the search for common antecedents |
| Q37924497 | Venous thromboembolism prophylaxis after hospital discharge: transition to preventive care |
| Q44800823 | Venous thromboembolism prophylaxis in a general hospital |
| Q36427613 | Venous thromboembolism risk and management in women with cancer and thrombophilia |
| Q37404403 | Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis |
| Q92901938 | Venous thromboembolism risk stratification for patients with lower limb trauma and cast or brace immobilization |
| Q82759577 | Venous thromboembolism risk stratification in medically-ill hospitalized cancer patients. A comprehensive cancer center experience |
| Q44602780 | Venous thromboembolism: What pharmacists know? What do they need? |
| Q36265592 | Venous thrombotic events in cancer: the bottom line |
| Q34984444 | White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study |
| Q47120217 | Whole exome sequencing in thrombophilic pedigrees to identify genetic risk factors for venous thromboembolism. |
| Q53321530 | [Arterial and venous thrombosis in lung cancer] |
| Q55443483 | [Clinical features in 23 lung cancer patients complicated with pulmonary thromboembolism]. |
| Q90481535 | [Lung involvement in hematologic systemic diseases] |
| Q55438845 | [Risk factors and prognosis of lung cancer combined with pulmonary embolism]. |
| Q84700920 | [Supportive therapy of urogenital tumors: diagnostic and therapy of common complications] |
Search more.